Psyence Biomedical PBM 深 沪
等待开盘 10-05 09:30:00 美东时间
5.16
-0.320
-5.84%
华盛通- 最 高5.6325
- 今 开5.52
- 成交量 7.51万股
- 最 低 5.12
- 昨 收 5.48
- 总市值 1968.19万
- 52周最高 26.1719
- 市盈率 静 --
- 换手率 1.97%
- 52周最低 1.92
- 委 比 -77.78%
- 总股本 381.43万
- 历史最高 392.0244
- 量 比 1.71
- 振 幅 9.35%
- 历史最低 3.8419
- 每 手 1
- 风险率 5.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Psyence BioMed's Texas subsidiary, TIRC, has signed a binding term sheet with PsyLabs granting exclusive U.S. rights to develop, supply, and distribute PsyLabs' pharmaceutical-grade ibogaine. The agreement includes an exclusive license, supply, and distribution arrangement, with TIRC paying up to $1.3 million in milestones, an annual exclusivity fee, and royalties. PsyLabs retains rights outside the U.S. The term sheet is subject to a definitive ...
09-28 11:00
Psyence Biomedical Agrees To Make Cash Investment Of Up To $5M In Psyence Labs
Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD). Texas Ibogaine Research Corporation (T...
09-23 19:02
Psyence BioMed Announces Strategic Ibogaine Investment
Psyence BioMed has agreed to invest up to $5 million in PsyLabs and exchange shares worth approximately $9 million each to support the development of a U.S. ibogaine program for Opioid Use Disorder. A subsidiary, TIRC, has been established in Texas to coordinate regulatory and clinical activities. The investment and share exchange aim to align the companies' resources for clinical research and manufacturing.
09-23 11:00
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
Psyence Biomedical Ltd. has established Texas Ibogaine Research Corporation (TIRC) to coordinate U.S. ibogaine development, supply, and clinical activities. TIRC will hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, with plans to engage in regulatory and clinical development. Jody Aufrichtig leads TIRC, aiming to advance research and development for U.S. patients.
09-14 11:00
Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
Psyence BioMed Ltd. welcomed President Trump's announcement supporting the accelerated development of ibogaine as a potential medical treatment in the U.S. The company, which specializes in nature-derived psychedelic compounds, holds a significant stake in PsyLabs, a GMP-compliant manufacturer of ibogaine hydrochloride. Psyence BioMed is positioned to contribute to the regulated clinical development of ibogaine, aligning with the federal governme...
08-18 21:23
美股夜盘 | 柏雅国际涨41.30%，Advanced Biomed涨31.21%
Digital Brands Group, Inc.涨-20.24%；Ryde Group涨-12.83%；Psyence Biomedical Ltd.涨-9.12%
07-20 08:05
Prestige Consumer Healthcare Announces agreement To Acquire LaCorium Health, A Leader In Australian Therapeutic Skin Care For ~150M
LaCorium AcquisitionThe Company today is also announcing a definitive agreement to acquire LaCorium Health ("LaCorium"), for approximately $150 million in cash. The transaction, subject to customary conditions, is
05-14 04:33
美股夜盘 | FST Corp.涨47.54%，Kyverna Therapeutics, Inc.涨35.84%
FST Corp.涨47.54%；Kyverna Therapeutics, Inc.涨35.84%；Aspire Biopharma Holdings, Inc.涨18.85%
04-22 15:01
美股夜盘 | FST Corp.涨54.92%，Kyverna Therapeutics, Inc.涨42.43%
FST Corp.涨54.92%；Kyverna Therapeutics, Inc.涨42.43%；Aspire Biopharma Holdings, Inc.涨17.63%
04-22 13:01
